Hungarian pharmaceutical company Gedeon Richter on Thursday said it entered into an exclusive licence agreement with UK-headquartered Hikma Pharmaceuticals to commercialise its drug denosumab, used to treat osteoporosis and fractures due to bone metastasis, in the United States.
Denosumab comprises two biosimilar products referencing the brands Prolia and Xgeva.
Under the agreement, Richter is responsible for the development of the products,
conducting both Phase 1 and Phase 3 global clinical studies, and will supply the products for the US market.
Hikma will be responsible for registering the products with the US Food and Drug Administration (FDA) and will have exclusive rights to commercialise them in the United States.
Richter is eligible for an upfront payment and milestone payments totalling “a double-digit million USD figure” under the financial terms of the agreement.
Read alsoCNN wanted to spread fake news about Hungary? – VIDEO
If you would like to support the work of the Daily News Hungary staff and independent journalism,
please make a donation here
please make a donation here
Hot news
Snow and sleet expected today in Hungary: here is where
Underpaid guest workers employed in Budapest instead of Hungarians?
Minister: Hungary’s pension system reliable
Austrians are flocking to Hungary to get cheap driving lessons
Hungarian billionaire buys foreign retail chain in Hungary
Fidesz: European left blackmails Hungary
